Timothy J Mcdonald

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8885026/timothy-j-mcdonald-publications-by-year.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112 papers	3,299 citations	30 h-index	56 g-index
121 ext. papers	4,421 ext. citations	7.8 avg, IF	5.07 L-index

#	Paper	IF	Citations
112	P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure. *Journal of Crohns and Colitis*, **2022**, 16, i256-i256	1.5	
111	OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. *Journal of Crohns and Colitis*, **2022**, 16, i023-i025	1.5	
110	Response to Comment on Meek et al. Reappearance of C-Peptide During the Third Trimester in Type 1 Diabetes Pregnancy: Pancreatic Regeneration or Fetal Hyperinsulinism? Diabetes Care 2021;44:1826-1834.. *Diabetes Care*, **2022**, 45, e43-e44	14.6	
109	Type 1 Diabetes Patients With Different Residual Beta-Cell Function but Similar Age, HBA1c, and Cardiorespiratory Fitness Have Differing Exercise-Induced Angiogenic Cell Mobilisation.. *Frontiers in Endocrinology*, **2022**, 13, 797438	5.7	1
108	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.. *Nature Communications*, **2022**, 13, 1379	17.4	3
107	Capturing the real-world benefit of residual β-cell function during clinically important time-periods in established Type 1 diabetes.. *Diabetic Medicine*, **2022**, e14814	3.5	0
106	Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 128-137	6.1	2
105	Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. *Diabetes Care*, **2021**, 44, 390-398	14.6	18
104	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. *Diabetes Care*, **2021**, 44, 511-518	14.6	6
103	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. *Gut*, **2021**, 70, 865-875	19.2	76
102	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. *Gut*, **2021**, 70, 1884-1893	19.2	93
101	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. *Diabetes Care*, **2021**, 44, 1243-1251	14.6	10
100	Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?. *Diabetes Care*, **2021**, 44, 1826-1834	14.6	3
99	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. *Diabetes*, **2021**, 70, 2092-2106	0.9	4
98	Clinical profiles of post-load glucose subgroups and their association with glycaemic traits over time: An IMI-DIRECT study. *Diabetic Medicine*, **2021**, 38, e14428	3.5	2
97	Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England. *British Journal of Cancer*, **2021**, 124, 1231-1236	8.7	19
96	Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation. *Health Technology Assessment*, **2021**, 25, 1-248	4.4	3

95	Measurement of Peak C-Peptide at Diagnosis Informs Glycemic Control but not Hypoglycemia in Adults With Type 1 Diabetes. *Journal of the Endocrine Society*, **2021**, 5, bvab127	0.4	0
94	Patient-led Remote IntraCapillary pharmacoKinetic Sampling (fingerPRICKS) for therapeutic drug monitoring in patients with inflammatory bowel disease. *Journal of Crohns and Colitis*, **2021**,	1.5	2
93	Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. *Journal of Crohns and Colitis*, **2021**,	1.5	13
92	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. *Archives of Disease in Childhood*, **2020**, 105, 957-963	2.2	3
91	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. *PLoS Medicine*, **2020**, 17, e1003149	11.6	18
90	Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. *Diabetologia*, **2020**, 63, 1258-1267	10.3	40
89	The challenge of diagnosing type 1 diabetes in older adults. *Diabetic Medicine*, **2020**, 37, 1781-1782	3.5	2
88	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. *Diabetologia*, **2020**, 63, 744-756	10.3	4
87	Parental experiences of a diagnosis of neonatal diabetes and perceptions of newborn screening for glucose: a qualitative study. *BMJ Open*, **2020**, 10, e037312	3	0
86	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. *PLoS ONE*, **2020**, 15, e0242360	3.7	2
85	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn Disease. *Gastroenterology*, **2020**, 158, 189-199	13.3	117
84	Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells. *Diabetologia*, **2020**, 63, 2605-2615	10.3	9
83	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. *Genome Medicine*, **2020**, 12, 109	14.4	3
82	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. *EBioMedicine*, **2020**, 58, 102932	8.8	2
81	Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual Cell Function. *Diabetes Care*, **2020**, 43, 2362-2370	14.6	6
80	Predictors of Recurrent Severe Hypoglycemia in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia During the HypoCOMPaSS Study. *Diabetes Care*, **2020**, 43, 44-52	14.6	6
79	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. *BMJ Open*, **2020**, 10, e034716	3	5
78	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149		

77	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149		
76	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149		
75	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149		
74	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts **2020**, 17, e1003149		
73	Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. *BMC Medicine*, **2019**, 17, 165	11.4	20
72	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. *Diabetologia*, **2019**, 62, 1601-1615	10.3	14
71	Stability of urinary albumin and creatinine after 12 months storage at -20 ℃ and -80 ℃. *Practical Laboratory Medicine*, **2019**, 15, e00120	1.7	3
70	The association between GAD65 antibody levels and incident Type 2 Diabetes Mellitus in an adult population: A meta-analysis. *Metabolism: Clinical and Experimental*, **2019**, 95, 1-7	12.7	4
69	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn disease: a prospective, multicentre, cohort study. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 341-353	18.8	224
68	Persistent C-peptide is associated with reduced hypoglycaemia but not HbA in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. *Diabetic Medicine*, **2019**, 36, 1092-1099	3.5	21
67	Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. *Diabetologia*, **2019**, 62, 1167-1172	10.3	48
66	Type 1 diabetes genetic risk score discriminates between monogenic and Type 1 diabetes in children diagnosed at the age of . *Diabetic Medicine*, **2019**, 36, 1694-1702	3.5	8
65	Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated neonatal diabetes show predominance of non-K-channel pathways. *BMJ Open Diabetes Research and Care*, **2019**, 7, e000721	4.5	4
64	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. *Diabetes Care*, **2019**, 42, e16-e17	14.6	15
63	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. *Diabetes Care*, **2019**, 42, 208-214	14.6	20
62	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 1103-1116	6.1	21
61	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. *Diabetes Care*, **2018**, 41, 705-712	14.6	36
60	A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes. *Diabetologia*, **2018**, 61, 862-869	10.3	20

59	Comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials". *Diabetes, Obesity and Metabolism*, **2018**, 20, 1549-1550	6.7	1
58	A high-sensitivity electrochemiluminescence-based ELISA for the measurement of the oxidative stress biomarker, 3-nitrotyrosine, in human blood serum and cells. *Free Radical Biology and Medicine* , **2018**, 120, 246-254	7.8	11
57	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. *Diabetologia*, **2018**, 61, 66-74	10.3	21
56	Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β-associated renal disease and can be symptomatic. *CKJ: Clinical Kidney Journal*, **2018**, 11, 453-458	4.5	5
55	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. *Diabetes Care*, **2018**, 41, 1486-1492	14.6	54
54	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. *Life Sciences, Society and Policy*, **2018**, 14, 20	3.2	5
53	Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. *Clinical Medicine*, **2017**, 17, 18-21	1.9	6
52	Screening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement. *Diabetologia*, **2017**, 60, 2168-2173	10.3	7
51	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. *Diabetes Care*, **2017**, 40, 1017-1025	14.6	73
50	Proinsulin is stable at room temperature for 24 hours in EDTA: A clinical laboratory analysis (adAPT 3). *PLoS ONE*, **2017**, 12, e0171716	3.7	2
49	Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 250-7	14.6	94
48	A cautionary tale: Unforeseen consequences of lean processing in a blood sciences laboratory. *Clinical Biochemistry*, **2016**, 49, 1311-1312	3.5	
47	Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes. *Diabetologia*, **2016**, 59, 2722-2726	10.3	33
46	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. *Diabetes Care*, **2016**, 39, 1879-1888	14.6	117
45	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. *Diabetes Care*, **2016**, 39, 337-44	14.6	141
44	Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic. *Diabetic Medicine*, **2016**, 33, 1554-1558	3.5	34
43	Low IgE Is a Useful Tool to Identify STAT3 Gain-of-Function Mutations. *Clinical Chemistry*, **2016**, 62, 1536-1538	5.5	4
42	Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function. *Methods in Molecular Biology*, **2016**, 1433, 93-102	1.4	5

41	Interleukin-1 antagonism in type 1 diabetes of long duration. *Diabetes and Metabolism*, **2016**, 42, 453-456	3.4	4
40	Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. *Annals of Clinical Biochemistry*, **2015**, 52, 672-4	2.2	5
39	Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues. *Clinical Biochemistry*, **2015**, 48, 1354-7	3.5	38
38	Investigating hyperkalaemia in adults. *BMJ, The*, **2015**, 351, h4762	5.9	9
37	Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. *Diabetes Care*, **2015**, 38, 323-8	14.6	76
36	The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. *Diabetic Medicine*, **2014**, 31, 403-11	3.5	12
35	Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes. *Diabetes Care*, **2014**, 37, 3333-5	14.6	16
34	Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. *Nature Genetics*, **2014**, 46, 812-814	36.3	328
33	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. *Diabetologia* , **2014**, 57, 1132-42	10.3	39
32	Diagnostic confusion? Repeat HbA1c for the diagnosis of diabetes. *Diabetes Care*, **2014**, 37, e135-6	14.6	8
31	Effect of the holiday season in patients with diabetes: glycemia and lipids increase postholiday, but the effect is small and transient. *Diabetes Care*, **2014**, 37, e98-9	14.6	6
30	The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a □cell phenotype. *Journal of Medical Genetics*, **2014**, 51, 165-9	5.8	57
29	Home urine C-peptide creatinine ratio can be used to monitor islet transplant function. *Diabetes Care*, **2014**, 37, 1737-40	14.6	4
28	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. *Diabetologia*, **2014**, 57, 187-91	10.3	188
27	Abkl□ung einer Hypokali□mie. *Praxis*, **2014**, 103, 341-345	0.1	
26	Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype. *Diabetologia*, **2013**, 56, 218-21	10.3	19
25	Cystatin C is not a good candidate biomarker for HNF1A-MODY. *Acta Diabetologica*, **2013**, 50, 815-20	3.9	7
24	Maturity onset diabetes of the young: identification and diagnosis. *Annals of Clinical Biochemistry*, **2013**, 50, 403-15	2.2	96

23	Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. *Pediatric Diabetes*, **2013**, 14, 181-8	3.6	22
22	Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. *BMJ Open*, **2013**, 3, e003193	3	9
21	Preanalytical sample handling of venous blood: how to ensure your glucose measurement is accurate and reliable. *Practical Diabetes*, **2013**, 30, 128-131	0.7	4
20	Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. *Diabetic Medicine*, **2013**, 30, 1342-8	3.5	10
19	The impact of insulin administration during the mixed meal tolerance test. *Diabetic Medicine*, **2012**, 29, 1279-84	3.5	17
18	Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. *Clinica Chimica Acta*, **2012**, 413, 927-32	6.2	30
17	Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. *BMC Endocrine Disorders*, **2012**, 12, 6	3.3	10
16	EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature. *PLoS ONE*, **2012**, 7, e42084	3.7	31
15	The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. *Diabetologia*, **2012**, 55, 1265-72	10.3	172
14	Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. *Diabetic Medicine*, **2012**, 29, 90-3	3.5	22
13	The impact of gender on urine C-peptide creatinine ratio interpretation. *Annals of Clinical Biochemistry*, **2012**, 49, 363-8	2.2	10
12	Using highly sensitive C-reactive protein measurement to diagnose MODY in a family with suspected type 2 diabetes. *BMJ Case Reports*, **2012**, 2012,	0.9	
11	Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. *Diabetes Care*, **2011**, 34, 286-91	14.6	96
10	High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes. *Diabetes Care*, **2011**, 34, 1860-2	14.6	76
9	A novel case of a raised testosterone and LH in a young man. *Clinica Chimica Acta*, **2011**, 412, 1999-2001	6.2	2
8	Response to Comment on: McDonald et al. High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes. Diabetes Care 2011;34:1860-1862. *Diabetes Care*, **2011**, 34, e187-e187	14.6	78
7	Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. *Diabetic Medicine*, **2011**, 28, 1034-8	3.5	26
6	Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. *Diabetic Medicine*, **2011**, 28, 1028-33	3.5	127

5	Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. *Diabetes Care*, **2011**, 34, 607-9	14.6	48
4	Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. *Clinical Chemistry*, **2009**, 55, 2035-9	5.5	48
3	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients		1
2	Diagnostic performance of the faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: a service evaluation in the South West of England		1
1	Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients		3